News

Soung discussed how new 52-week data support icotrokinra's recent FDA approval, marketed as Icotyde.

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

KDIGO updates in IgA nephropathy highlight lower proteinuria targets, improved risk tools, and an expanding landscape of targeted and combination therapies.

This interview at AAD 2026 highlights Nguyen's views on the biggest drivers of patient dissatisfaction in dermatology practice settings.

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

This interview at AAD 2026 highlights tips for clinicians in dermatology practices who want to improve patient communication and satisfaction.

Corey Cavanaugh, DO, and Abdallah Geara, MD, separately share their perspectives on the clinical clues for IgAN diagnosis, including hypertension and microscopic hematuria.

These new data on spesolimab (Spevigo) in adults with generalized pustular psoriasis highlight long-term findings with the treatment.

Deep learning applied to routine ECGs identified COPD up to 15 months earlier, supporting earlier intervention and risk stratification strategies.

AstraZeneca's investigational IL-33–targeting antibody tozorakimab met its primary endpoint in both the phase III OBERON and TITANIA trials.

The FDA has approved a labeling update for 1 mg epinephrine nasal spray permitting use in any patient weighing 33 lbs or more.

A post-hoc analysis of phase 3 trials found tapinarof cream 1% produced skin clearance and itch relief as early as week 1 in patients aged 2 years and older.

Study shows microglia-driven hippocampal remodeling may connect chronic pain to depression, highlighting the importance of timing for behavioral interventions.

The indication makes insulin icodec the first new class of basal insulin to reach US patients in more than 2 decades.

Janiene Luke, MD, co-chair of the Skin of Color Society (SOCS) Scientific Symposium, speaks about complex cases in dermatology and other topics covered at the meeting.

Experts discuss major advances in glomerular disease research and care, including molecular technologies, biomarker discovery, APOL1-mediated kidney disease, and evolving clinical trial design and endpoints.

Temitayo Ogunleye, MD, co-chair of the Skin of Color Society Scientific Symposium, speaks with HCPLive about the meeting's guiding theme and topics.

Nuckols discusses her recent study highlighting a correlation between pregnancy complications, increased psychosocial stress, and cardiovascular disease risk.

Population study links respiratory allergies to hoarseness, throat clearing, and vocal fatigue, with greater symptom burden in women and unified airway implications.

Kramer, the president of the American College of Cardiology, discusses the organization’s recent movement to adapt rapidly growing AI technology to clinical care.

Fahed explains how a multi-ancestry metabolic poly genetic risk score from over 8.5 million individuals points to the utility of global collaboration in genetic research.

New research identifies dietary epitopes driving oral tolerance, offering insight into Treg responses, early exposure, and future food allergy therapies.

Bhatt shares his thoughts on the recently released dyslipidemia guidelines, highlighting the return of goal-based LDL-C therapy and Lp(a) receiving a COR 1 suggestion.

Su emphasized how care should be shifted to reflect known impacts of NNAALs on obstetric care.

Gerlud explains why exocrine pancreatic insufficiency is often missed, even in high-risk patients.

Witkowski discusses the data presented at ATTD 2026, highlighting the investigative anti-CD40L monoclonal antibody in facilitating insulin independence.

Angkeow discusses a recent study finding that PhIP-Seq analysis links diverse IgG responses to food allergy phenotypes.

Geara breaks down the clinical framework for the modern era of IgA nephropathy.